ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "safety and tuberculosis"

  • Abstract Number: 2628 • ACR/ARHP Annual Meeting 2016

    Retention of Use and Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: A Patient Record Assessment in a Compassionate Use Programme in South Africa, a Tuberculosis Endemic Country

    I Louw1, M Ally2, DC Janse van Rensburg2, E Van Duuren3, D Nel3, H Miller-Janson4, M de Necker4, JC de Beer4 and H Duvenhage5, 1Panorama Medical Centre, Cape Town, South Africa, 2University of Pretoria, Pretoria, South Africa, 3Jacaranda Hospital, Pretoria, South Africa, 4HEXOR (PTY) Ltd, Pretoria, South Africa, 5Bristol-Myers Squibb, Johannesburg, South Africa

    Background/Purpose: South Africa is a tuberculosis (TB) endemic country having one of the highest TB infection rates in the world with close to 1000 cases…
  • Abstract Number: 1222 • ACR/ARHP Annual Meeting 2015

    The Risk of Tuberculosis (TB) in Rheumatoid Arthritis Patients Treated with TNF Inhibitors and the Safety of Resuming Biologic Dmards for Patients Who Developed TB after Anti-TNF Treatment

    Soo-Kyung Cho1, Dam Kim1, Hye-Jin Jeong2, Il Woong Sohn2, Soyoung Won3, Minkyung Han3, Jiyoung Lee3, Eun Jin Jang4, Sang-Cheol Bae1 and Yoon-Kyoung Sung1, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 2Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 4Information Statistics, Andong National University, Andong-si, South Korea

    Background/Purpose: The association between TNF inhibitor (TNFI) treatment and the development of tuberculosis (TB) has been confirmed through several observational studies. Current guidelines strongly recommend…
  • Abstract Number: 1817 • ACR/ARHP Annual Meeting 2012

    The Role of Repeating Tuberculin Skin Tests During Biologic Therapy

    Joseph R. Lutt1 and Kevin L. Winthrop2, 1Colorado Center for Arthritis & Osteoporosis, Boulder, CO, 2Dept of Infectious Disease, Oregon Health & Science University, Portland, OR

    The Role of Repeating Tuberculin Skin Tests during Biologic TherapyBackground/Purpose: Prior to starting biologic therapy, it is recommended that all patients be screened for tuberculosis…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology